ERBB2 and neoplasm: We have previously developed the viral capsid-derived fusion protein, HerPBK10, which targets noncovalently attached therapeutic molecules to human epidermal growth factor receptor 2- positive (HER2+) cells, including breast, ovarian, and glioma cancer cells, and mediates penetration into the tumor cells, resulting in tumor-targeted toxicity [17]–[23].